<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00916552</url>
  </required_header>
  <id_info>
    <org_study_id>EPO1</org_study_id>
    <nct_id>NCT00916552</nct_id>
  </id_info>
  <brief_title>Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolar Disorder</brief_title>
  <official_title>The Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Patients With Treatment Resistant Depression and in Patients With Remitted Bipolar Disorder - a Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lars Vedel Kessing, professor, MD, DMSc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ministry of Science, Technology and Innovation, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Max-Planck-Institute of Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression and bipolar disorder (mania and depression) may be related to problems with nerve&#xD;
      cells not being regenerated as fast as normal and are accompanied by cognitive difficulties&#xD;
      including memory, attention and planning problems. There is thus a need for better, more&#xD;
      efficient treatments with effects on cognitive function. Erythropoietin (Epo) is involved in&#xD;
      brain repair and may be a candidate for future treatment strategies. The investigators have&#xD;
      demonstrated that a single dose of Epo improves mood and reduces the processing of negative&#xD;
      emotional information in healthy volunteers similar to effects seen with antidepressants.&#xD;
      With the current study the investigators aim to build upon this discovery by investigating&#xD;
      whether repeated Epo administration has antidepressant effects and is able to reverse&#xD;
      cognitive difficulties in patients with depression or bipolar disorder. It is hypothesized&#xD;
      that Epo will improve mood in treatment-resistant depression and improve cognitive function&#xD;
      in this group and in patients with bipolar disorder in remission. If the study reveals&#xD;
      beneficial effects of Epo, this would highlight Epo as a candidate compound for future&#xD;
      treatment of depression and bipolar disorder, with the potential to directly promote brain&#xD;
      repair mechanisms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a) For treatment-resistant depressed patients: Antidepressant effect measured with the Hamilton Depression Rating Scale (HDRS); b) For bipolar patients in remission: Memory measured with the Rey Auditory Verbal Memory Test.</measure>
    <time_frame>a) Baseline and weeks 5, 9 and 14; b) Baseline and weeks 9 and 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>a) For treatment-resistant depressed patients: number of remissions measured with the HDRS; b) For bipolar patients in remission: sustained attention measured with the RVIP and facial expression recognition.</measure>
    <time_frame>a) Baseline and weeks 5, 9 and 14; b) Baseline and weeks 9 and 14</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Mood Disorders</condition>
  <arm_group>
    <arm_group_label>Erythropoeitin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40.000 IU, epoetin alfa; Janssen-Cilag</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>40.000 IU/ml epoetin alfa is administered as intravenous infusions over 15 min weekly for 8 weeks.</description>
    <arm_group_label>Erythropoeitin</arm_group_label>
    <other_name>Eprex</other_name>
    <other_name>Epo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treatment-resistant depression (defined as failure to respond to at least 2 different&#xD;
             types of antidepressants) and an HDRS score of at least 17&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  Bipolar disorder in remission (HDRS score of max 14 and Young Mania Scale score of max&#xD;
             14) and subjective complaints of moderate to severe cognitive problems on the&#xD;
             Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)&#xD;
             (Fava et al 2006) (score at least 4 on at least 2 domains)&#xD;
&#xD;
          -  Unchanged antidepressant or mood stabilizing treatment for at least 2 weeks prior to&#xD;
             and during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Schizophrenia/ schizoaffective disorder&#xD;
&#xD;
          -  Dependence on or abuse of drugs (including alcohol and benzodiazepines corresponding&#xD;
             to more than 22.5 mg Oxazepam daily)&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to inclusion&#xD;
&#xD;
          -  Previous Epo-treatment&#xD;
&#xD;
          -  Known allergy or antibodies against Epo&#xD;
&#xD;
          -  Present or past malignancies&#xD;
&#xD;
          -  Epilepsy or epilepsy in first degree family Diagnosis (past or present) of a&#xD;
             cardiovascular or cerebrovascular disease&#xD;
&#xD;
          -  Untreated or not sufficiently treated arterial hypertension (&quot;therapy-resistant&#xD;
             hypertension&quot;)&#xD;
&#xD;
          -  Initial hematocrit &gt; 50% (males) or &gt; 48% (females)&#xD;
&#xD;
          -  Initial platelet count above normal range of laboratory&#xD;
&#xD;
          -  Initial reticulocyte count below norma range of laboratory&#xD;
&#xD;
          -  Past thromboembolic events or thromboembolic events in first degree family (increased&#xD;
             thromboembolic risk)&#xD;
&#xD;
          -  Contraindications against prophylactic thrombosis treatment&#xD;
&#xD;
          -  Myeloproliferative disorder, polycythemia&#xD;
&#xD;
          -  Present immunosuppressive treatment with cyclosporin&#xD;
&#xD;
          -  Overweight (BMI &gt; 30) or body weight of less than 45 kg or over 95 kg&#xD;
&#xD;
          -  Acute suicidal risk, present or previous suicide attempts in the past 2 years&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Women who presently use contraceptive pills&#xD;
&#xD;
          -  Sexually active women with child bearing potential who refuse to use double barrier&#xD;
             anticonception methods&#xD;
&#xD;
          -  Unwillingness or inability to comply with the requirements of the protocol including&#xD;
             the presence of any condition (physical, mental, or social) that is likely to affect&#xD;
             the subject's ability to comply with the protocol&#xD;
&#xD;
          -  Present illness which in investigator's opinion could affect the patient's&#xD;
             participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars V Kessing, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Copenhagen University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>June 8, 2009</study_first_submitted>
  <study_first_submitted_qc>June 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2009</study_first_posted>
  <last_update_submitted>November 8, 2012</last_update_submitted>
  <last_update_submitted_qc>November 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Lars Vedel Kessing, professor, MD, DMSc.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Erythropoietin</keyword>
  <keyword>Epo</keyword>
  <keyword>depression</keyword>
  <keyword>bipolar disorder</keyword>
  <keyword>cognition</keyword>
  <keyword>cognitive function</keyword>
  <keyword>antidepressant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

